Logo

Lilly and Incyte's Olumiant (baricitinib) Receive the US FDA’s Approval for the Treatment of Hospitalized Patients with COVID-19

Share this
Lilly and Incyte's Olumiant (baricitinib) Receive the US FDA’s Approval for the Treatment of Hospitalized Patients with COVID-19

Lilly and Incyte's Olumiant (baricitinib) Receive the US FDA’s Approval for the Treatment of Hospitalized Patients with COVID-19

Shots:

  • The US FDA has approved Olumiant for COVID-19 in hospitalized adults who required supplemental oxygen, invasive/non-invasive mechanical ventilation, or ECMO for 14 days or until hospital discharge
  • The approval was based on 2 P-III (ACTT-2) & (COV-BARRIER) studies including (COV-BARRIER OS 7 addendum) study to evaluate Olumiant (4mg, qd). The findings revealed that there were no additional safety signals associated with the usage of Olumiant
  • Olumiant is the 1st JAK inhibitor & has been available in the US under a EUA since Nov 2020. Lilly has submitted the applications to multiple regulatory agencies globally for approval or authorization with expected regulatory decisions shortly

Ref: PRNewswire | Image: Lilly

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions